Completed PHASE1 INTERVENTIONAL 1-arm NCT02142530

Carfilzomib Plus Belinostat in Relapsed/Refractory NHL

Carfilzomib Plus Belinostat in Relapsed/Refractory Non-Hodgkin Lymphoma Subtypes: A Phase 1 Study

Sponsor: Massachusetts General Hospital

Conditions Diffuse Large B-cell Lymphoma Follicular Lymphoma Mantle Cell Lymphoma Non-Hodgkin Lymphoma Peripheral T-cell Lymphoma

Interventions Belinostat Carfilzomib

Updated 7 times since 2017 Last updated: Jan 23, 2018 Started: Oct 31, 2014 Primary completion: Mar 31, 2017 Completion: Jan 31, 2018

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02142530, this PHASE1 trial focuses on Diffuse Large B-cell Lymphoma and Follicular Lymphoma and remains completed. Sponsored by Massachusetts General Hospital, it has been updated 7 times since 2014, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Feb 2018 — Jun 2018 [monthly]

Completed PHASE1

Status: Recruiting → Completed

▶ Show 2 earlier versions

Feb 2017 — Feb 2018 [monthly]

Recruiting PHASE1
Jan 2017 — Feb 2017 [monthly]

Recruiting PHASE1

First recorded

Oct 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Massachusetts General Hospital
National Comprehensive Cancer Network

Data source: Massachusetts General Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Boston, United States